---
document_datetime: 2025-07-14 16:50:29
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/axumin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: axumin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 8.2442278
conversion_datetime: 2025-12-14 21:35:55.104788
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Axumin

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber    | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | A.ADMINISTRATIVECHANGES-A.4 Change | 11/07/2025                          |                                          | Annex II,                       |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000281183                     | in the name and/or address of:a manufacturer(including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate usedinthemanufactureoftheactive substance (where specified in the technical dossier)where noPh.Eur.Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient(where specified in the technical dossier) - Accepted A.5Change in thename and/or address of a manufacturer/importerofthefinished product (including batch release or quality control testing sites)-A.5.a The activities for which the manufacturer/importer is responsible includebatchrelease-Accepted   |            |     | Labelling and PL   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------|
| Variation typeIB / EMA/VR/0000281167  | B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product - B.1I.e.2.z Otherchanges-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/07/2025 | N/A |                    |
| Variation type IA / EMA/VR/0000240003 | A.ADMINISTRATIVECHANGES-A.7 Deletion ofmanufacturingsitesfor an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place,orsupplier of a startingmaterial, reagent orexcipient(when mentionedin the                                                                                                                                                                                                                                                                                                                                                                                                                         | 12/12/2024 | N/A |                    |

<div style=\"page-break-after: always\"></div>

|                                       | dossier)*- Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |                        |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|
| Variation type IB / EMA/VR/0000227755 | This was an application for a group of variations. B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier)-B.II.e.7.b Replacement or additionofasupplier-Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediateused in themanufactureof the finished product-B.II.b.3.z Other changes- Accepted B.II.b.2 Change to importer,batch release arrangements and quality control testing of the finished product-B.1I.b.2.a Replacementoradditionofasitewhere batch control/testing takes place - Accepted B.II.b.2.cReplacement or addition of a manufacturerresponsibleforimportation and/or batch release - B.1I1.b.2.c.2 Including batch control/testing - Accepted B.II.b.1Replacementor addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.I1.b.1.a Secondary packaging site-Accepted | 03/10/2024 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|                                       | B.II.b.1 Replacement or addition of a manufacturingsiteforpartor all of the manufacturing process of the finished product - B.1II.b.1.f Site where any manufacturing operation(s) take place, exceptbatchrelease，batchcontrol,and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunologicalmedicinal products-Accepted                                                                                                                                                                                      |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000224587 | Thiswas an applicationfor agroupof variations. B.II.b.2 Change to importer,batch release arrangements and quality control testing of the finished product-B.1I.b.2.a Replacementoradditionofasitewhere batch control/testing takes place - Accepted B.1.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturingprocessoftheactive substance -B.I.b.2.a Minor changes to an approved test procedure- Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance,startingmaterial/intermediate/ | 27/08/2024 | N/A |

<div style=\"page-break-after: always\"></div>

| reagent used in the manufacturing process  of the active substance - B.I.b.1.d Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) - Refused   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|